Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Nicholas A Keks, Judy Hope, Darren Schwartz, et al.
CNS Drugs (2020) Vol. 34, Iss. 5, pp. 473-507
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors
Despoina Aslanoglou, Suzanne Bertera, Marta Sánchez‐Soto, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 74
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
I. Laszlovszky, Ágota Barabássy, György Németh
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3652-3673
Open Access | Times Cited: 59
Dopamine D1–D5 Receptors in Brain Nuclei: Implications for Health and Disease
K. Kawahata, David I. Finkelstein, Kohji Fukunaga
Receptors (2024) Vol. 3, Iss. 2, pp. 155-181
Open Access | Times Cited: 12
New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists
Aineng Peng, Chai Jian-bo, Haiyuan Wu, et al.
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 607-620
Open Access | Times Cited: 10
Baseline symptom-related white matter tracts predict individualized treatment response to 12-week antipsychotic monotherapies in first-episode schizophrenia
Ying Chen, Shanming Liu, Bo Zhang, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Second‐generation antipsychotic‐induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database
Takumi Ebina, Kunihiro Iwamoto, Masahiko Ando, et al.
Psychiatry and Clinical Neurosciences (2025)
Open Access | Times Cited: 1
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Pavel Mohr, Jiří Masopust, Miloslav Kopeček
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 27
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
Michele Fusaroli, Emanuel Raschi, Valentina Giunchi, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 9, pp. 727-736
Open Access | Times Cited: 27
Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Tibor Štark, Serena Di Martino, Filippo Drago, et al.
Pharmacological Research (2021) Vol. 174, pp. 105938-105938
Closed Access | Times Cited: 32
Schizophrenia and Related Psychoses

(2025), pp. 1-278
Closed Access
Methods of correction of hyperprolactinemia induced by antipsychotics: current state of the problem and development prospects
Г. Н. Мазо, Ya V Yakovleva
V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY (2024) Vol. 58, Iss. 2, pp. 107-115
Open Access | Times Cited: 3
Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
Claudio Brasso, Gianluca Colli, Rodolfo Sgro, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 921-921
Open Access | Times Cited: 8
The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
Stephan Hjorth
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 18
Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia
Kristen M. Ward, Leslie Citrome
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 4, pp. 399-409
Closed Access | Times Cited: 2
Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: efficacy, safety, and cognitive impacts. A narrative review
Valerio Ricci, Alessandro Sarni, Giovanni Martinotti, et al.
International Clinical Psychopharmacology (2024)
Closed Access | Times Cited: 2
Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis
David D. Kim, Alasdair M. Barr, Lulu Lian, et al.
Schizophrenia (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 17
Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review
Luyao Cai, Guanjie Chen, Haichen Yang, et al.
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 4, pp. 249-260
Closed Access | Times Cited: 6
Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study
Leire Zazu, Teresa Morera‐Herreras, Montserrat García, et al.
European Neuropsychopharmacology (2021) Vol. 50, pp. 107-111
Closed Access | Times Cited: 14
Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
André Do, Kamyar Keramatian, Ayal Schaffer, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 14
Effect of Novel Antipsychotics on Energy Metabolism — In Vitro Study in Pig Brain Mitochondria
Matej Ľupták, Zdeněk Fišar, Jana Hroudová
Molecular Neurobiology (2021) Vol. 58, Iss. 11, pp. 5548-5563
Closed Access | Times Cited: 13
Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment
Tommaso B. Jannini, Andrea Sansone, Rodolfo Rossi, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 9, pp. 1065-1080
Closed Access | Times Cited: 9
Early Onset of Tardive Dyskinesia in an Antipsychotic-Naive Patient Treated With Low-Dose Cariprazine
Konstantinos Tsamakis, Maria Pantazidi, Evangelos Alevyzakis, et al.
Journal of Clinical Psychopharmacology (2024)
Closed Access | Times Cited: 1
A review on side effect management of second generation antipsychotics to treat schizophrenia: a drug safety perspective
Wolfgang Strube, Elias Wagner, Jurjen J. Luykx, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 6, pp. 715-729
Closed Access | Times Cited: 1
Efficacy and tolerability of brexpiprazole – a new antipsychotic drug from the group of dopamine D2 receptor partial agonists
Przemysław Bieńkowski, Adam Wichniak
Psychiatria Polska (2024) Vol. 58, Iss. 2, pp. 237-248
Open Access | Times Cited: 1
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Eva-Maria Tsapakis, Michael Treiber, Calypso Mitkani, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5637-5637
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top